Antibacterial property and clinical effect of gatifloxacin, a novel quinolone antibacterial agent

Folia Pharmacologica Japonica

Volumn 121, Issue 6, 2003, Pages 447-456

  Hosaka, Masaki ^a  

^a KYORIN PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Gatifloxacin; Pharmacokinetics pharmacodynamics (PK PD); Quinolone; Respiratory quinolone

Indexed keywords

AMPICILLIN; CIPROFLOXACIN; CLARITHROMYCIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); ERYTHROMYCIN; GATIFLOXACIN; LEVOFLOXACIN; SPARFLOXACIN;

ABSCESS; ANAEROBIC BACTERIUM; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; CHLAMYDIA; DRUG ACTIVITY; DRUG APPROVAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; EAR INFECTION; ENZYME INHIBITION; ERADICATION THERAPY; EYE INFECTION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; GYNECOLOGIC DISEASE; HAEMOPHILUS INFLUENZAE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MYCOPLASMA; PENICILLIN RESISTANCE; PHARMACODYNAMICS; RESPIRATORY TRACT INFECTION; REVIEW; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; SURGICAL INFECTION; URINARY TRACT INFECTION;

ANIMALS; ANTI-INFECTIVE AGENTS; BACTERIA; CLINICAL TRIALS; DNA GYRASE; DNA TOPOISOMERASE IV; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HALF-LIFE; HUMANS; RESPIRATORY TRACT INFECTIONS; TABLETS; TREATMENT OUTCOME; URINARY TRACT INFECTIONS;

EID: 0037782485     PISSN: 00155691     EISSN: None     Source Type: Journal    
DOI: 10.1254/fpj.121.447     Document Type: Review

References (19)

1. Miyashita N, Niki Y, Kishimoto T, Nakajima M and Matsushima T: In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp. Antimicrob Agents Chemother 41, 1331-1334 (1997)
2. Ishida K, Kaku M, Irifune K, Mizukane R, Takemura H, Yoshida R, Tanaka H, Usui T, Tomono K, Suyama N, et al: In-vitro and in-vivo activity of a new quinolone AM-1155 against Mycoplasma pneumoniae. J Antimicrob Chemother 34, 875-883 (1994)
3. Yamamoto T, Kusajima H, Hosaka M, Fukuda H, Oomori Y and Shinoda H: Uptake and intracellular activity of AM-1155 in phagocytic cells. Antimicrob Agents Chemother 40, 2756-2759 (1996)
4. Kishii R, Takei M, Fukuda H, Hayashi K and Hosaka M: Contribution of the 8-methoxy group to the activity of gatifloxacin against type II topoisomerases of Streptococcus pneumoniae. Antimicrob Agents Chemother 47, 77-81 (2003)
5. Nakashima M, Uematsu T, Kosuge K, Kusajima H, Ooie T, Masuda Y, Ishida R and Uchida H: Single-and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. Antimicrob Agents Chemother 39, 2635-2640 (1995)
6. Niki Y, Hashiguchi K, Miyashita N, Nakajima M and Matsushima T: Influence of gatifloxacin, a new quinolone antibacterial, on pharmacokinetics of theophylline. J Infect Chemother 5, 156-162 (1999)
7. Grasela DM, LaCreta FE, Kollia GD, Randall DM and Uderman HD: Open-label, nonrandomized study of the effects of gatifloxacin on the pharmacokinetics of midazolam in healthy male volunteers. Pharmacotherapy 20, 330-335 (2000)
8. Lister PD: Pharmacodynamics of gatifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model: impact of area under the curve/MIC ratios on eradication. Anrimicrob Agents Chemother 46, 69-74 (2002)
9. Ambrose PG, Owens RC, Quitiliani R, Yeston N, Crowe HM, Cunha BA and Nightingale CH: Antibiotic use in the critical care unit. Crit Care Clin 14, 283-308 (1998)
10. Wright DH, Brown GH, Peterson ML and Rotschafer JC: Application of fluoroquinolone pharmacodynamics. J Antimicrob Chemother 46, 669-683 (2000)